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2Abstract
Background. Public health research provides evidence for practice across fieldsincluding health care, health promotion and health surveillance. Levels of public healthresearch vary markedly across European Union (EU) countries, and are lowest in theEU’s new member states (in Central and Eastern Europe and the Mediterranean).However, these countries now receive most of the EU’s Structural Funds, some of whichare allocated to research.
Methods. STEPS, an EU-funded study, sought to assess support for public healthresearch at national and European levels. To identify support through the Structuralfunds, STEPS drew information from country respondents and internet searches for alltwelve EU new member states.
Results. The EU allocates annually around €7 billion through the Structural Funds formember states’ own use on research. These funds can cover infrastructure, academicemployment, and direct research grants. The programmes emphasise links to business.Support for health research includes major projects in biosciences, but direct supportfor public health research was found in only three countries – Cyprus, Latvia andLithuania.
Conclusions. Public health research is not prioritised in the EU’s Structural Fundsprogramme in comparison with biomedicine. For the research dimension of the newEuropean programme for Structural Funds 2014-2002, ministries of health shouldpropose public health research to strengthen the evidence-base for European publichealth policy and practice.
3Introduction
Public health, undertaken at organisational and system level through diseaseprevention and improving the efficiency and effectiveness of health care, contributesimportantly to population health and social wellbeing. Evidence is needed to developpublic health policies and practice.
Work in a previous EU study, SPHERE, described public health research from aEuropean perspective [1]. A strong geographical gradient in publication rates, highest inthe Scandinavian countries and UK and lowest in the southern and Eastern Europe, wasfound for all public health publications and within six sub-disciplinary themes [2].STEPS (Strengthening Public Health Research in Europe) was developed and fundedthrough the EU’s Science in Society programme to investigate the gradient further. Theobjective of STEPS was to assess the public health research systems in Europe and thecontribution of civil society organisations to health research in the EU ‘new memberstates’.
STEPS held workshops at national level in the 12 EU ‘new member states’ – the tencountries in Central Eastern Europe (Bulgaria, Czech Republic, Estonia, Hungary, Latvia,Lithuania, Poland Romania, Slovakia and Slovenia) and two in the Mediterranean(Cyprus and Malta) joining the EU in 2004 and 2007. The workshops, led by civil societyorganisations and involving researchers and ministries of health, were focused onnational public health research structures and perspectives [3]. STEPS also developedcountry health research profiles for all 27 EU countries, describing funding of healthresearch and support for universities and national research institutes [4]. Theworkshops and country profiles showed that all countries have strategies for researchoverall, but fewer have strategies specifically for health research, nor for public healthresearch [5]. National governments provide most funding, with non-profit foundations;there is no contribution by the commercial sector.
4The European Union funds research directly through the European Commission’sDirectorate for Research and Innovation. In the EU Seventh Framework Programme,2007-2013, health is a leading research theme, with €1bn allocated per annum. Withinthis, one of three funding strands is for public health research, which has supportedmore than 70 collaborative projects in Europe over the first three years [6].
However, the STEPS country workshops and profiles revealed a second stream offunding from the EU for research – from its Structural Funds. These funds form arounda quarter of the EU’s budget, and are directed towards support for poorer countries andregions within the Union. The use of the Structural Funds directly for health serviceshas been reported [7] and is the subject of a collaborative study EUREGIO III [8]. Thepotential for use of the Structural Funds for public health research is investigated here.
Methods
Public health research was defined broadly as research at health system andorganisational levels, including health care, health promotion and health surveillance,differing from biomedical research at laboratory and clinical levels. The EuropeanCommission’s web sites Erawatch [9] and Pro-Inno Policy TrendChart [10] providesbaseline country information (reporting up to 2009 when accessed in 2011) across allareas of research, and with a primary emphasis towards research for technology andbusiness. Information was recorded for the twelve countries joining the EuropeanUnion in 2004 and 2007.
Students from EU new member states attending the UCL School of Eastern Europeanand Slavonic Studies identified national web page resources about the Structural Fundsin their own languages, and provided an initial scoping of the data available. Thecountry partners in STEPS were also tasked to determine the information on the use ofthe Structural Funds for research, and to provide overview reports. Structures forcommissioning health research by country were also available through STEPS [4].
5While the Structural Funds were developed within a common template of funding fromthe European Commission, the 12 new member states each record the information indifferent ways, in different categories and with different levels of detail. Therefore,further searches were made of national web pages using Google Translate. The findingsof these searches were summarised and brought together for comparison.
Results
The European Union’s budget, comprising just over 1% of total GNP of the memberstates, is allocated in two major tranches – 43% for ‘natural resources’ (mainly thecommon agricultural policy), and 37% for ‘cohesion policy’. (The budget for research,education and training is around 7% of the total, and for the Health Directorate only0.07%.) In the period 2007-2013, the EU has allocated most of the Structural Funds tothe 12 EU ‘new’ member states, which have levels of GDP less than 75% of the EUaverage [11]
There are three funds for Cohesion Policy [12]. The European Regional DevelopmentFunds (ERDF) are “helping regions to anticipate and promote economic change throughinnovation and the promotion of the knowledge society”. The European Social Funds(ESF) are “strengthening competitiveness and employment by … investment in humanresources, the development of qualifications and competences, [and] the disseminationof information and communication technologies”. The third, much small fund, CohesionFunds (CF) contributes in the same ways as ERDF and ESF, and provides enhancedsupport for the smaller countries.
Allocations within the Structural Funds are negotiated by each country with theEuropean Commission’s Directorate for Regions. The Commission sets the total sum(mainly based on population), reporting structure (Operational Programmes) andbroad priorities (which included R&D), while member states determine the balance ofthese resource against their own priorities. Funds are allocated in the EuropeanRegional Development Funds for ‘physical’ infrastructures, and in the European SocialFund for ‘human’ resources. Allocations in the Operational Programmes that support
6research included university and science buildings, studentships and other training, andformal research calls.
How much funding? How is it used?The Structural Funds are spent on programmes devised and implemented by themember states, not centrally by the European Commission. However, countryprogrammes are agreed with the Commission, and follow EU policies. Over the fullperiod 2007-2013, around €86 billion, almost 25% of the total, is described as directedto research and innovation [13]. Of this, €50 billion is for “R&D and innovation in thenarrow sense” – including €10billion infrastructure, €9 billion for investment in firms,
€6 billion each for R&TD research centres, assistance to SMEs, and improvement ofnetworks, €5 billion in developing human potential, and €3 billion for SMEsenvironmentally-friendly products and processes.
A request for information directly to the European Commission received the followingreply: “Concerning the rate of implementation of this €86 billion, the latest availablefigures (Annual Implementation Reports 2009, provided by the Member States in July2010) show that about € 30 billion have been allocated to specific projects (out of which
€16 billion for R&D&I in a narrow sense). The remaining part can be committed beforethe end of the 2013. Moreover, about 3 % of the €30 billion (and 5% of the €16 billion)have been allocated to specific projects in the area of Human Health.” [correspondenceto author]
Little information is published by the Commission on the actual use of the StructuralFunds in the current programme, except gross expenditures. On the web page forCohesion Policy [14], there is a drop-down menu for Projects. The 12 EU countries havetogether 56 projects listed, across engineering, technology and life sciences. Fiveprojects listed are health-related, including organisation of cross-border care (CzechRepublic), an ambulatory care centre (Slovakia), breast screening (Poland), support forpharmaceutical information (Hungary) and a molecular genomics centre (Malta).However, the first two are service developments rather than research, and the last threeare laboratory technology rather than public health research.
7Use for health research in new member statesSTEPS used national web pages to identify the use of Structural Funds for healthresearch in the EU new member states. The majority of these 12 countries had generalR&D levels well below the EU average at the beginning of the period, at 0.6% of GNP orless, although two countries, Czech Republic and Slovenia, at 1.6% were closer to theEU’s average level of 1.9%, with Hungary, Estonia, and Lithuania at between 1% and0.8%. The overall allocation of the Structural Funds is strongly influenced by thepopulation size of the country – Poland receives a quarter of the total, and smallcountries gain much less. However, the information available from the larger countriesis less satisfactory than in some smaller countries, and the other countries provideimportant examples of alternative approaches.
Some countries, eg Estonia, Latvia, Lithuania and Slovakia, stand out in using theStructural Funds actively for research, and a few have developed competitive researchcalls from their funds. Some countries have put funding primarily into ‘centres’, egSlovenia. And in some countries, for example Malta and Slovakia, there is evident use ofthe ESF human resources funds to promote research capacities, with masters, doctorateand post-doctorate programmes. Bulgaria, by contrast, has apparently no directinvestment for research, although innovation could be supported in “R&D institutionsand organizations, municipalities, private or public bodies including NGOs”.
The funds are administered through Operational Programmes in very different ways[Table 1]. A minority of countries use their existing research management institutions –for example, Cyprus placed its Structural Funds for research in the Research PromotionFoundation. In contrast, Malta placed €20m for a molecular genetics centre within anagency working under the Ministry of Finance. Often it was not clear which organizationis managing the funding. While in the main the allocations were not identified toacademic fields, in a few countries there were developments of biomedical centres withcapital costs – for example, Czech Republic proposes a molecular biology centre outsidePrague of €100m. Only in one country, Lithuania, was there evidence of research for
8public health research, under the title ‘administrative capacity and efficient publicadministration’
Discussion
Understanding of the use of the Structural Funds for health research is limited by thedata sources. The European Commission’s internet sites provide only high-levelinformation on country research systems [9, 10]. The European Commission-fundedstudy of the use of the Structural Funds for health [8] does not cover health research.STEPS Country respondents have described national public health research structures[4], and some more detailed information can be found on country web pages in nationallanguages. This contrasts with information about research available through theEuropean Commission Directorate for Research, which has well-advertised calls andreports at the end of thematic programmes (although the underlying databases remaindifficult to interrogate [15]).
The budget available for research through the Structural Funds appears, at least onpaper, to be equal in size to the total available for the EU’s Research Programme. But thetwo programmes are managed separately by two European Commission directorates.The Framework Research Programme has a system of National Focal Points, oftenmembers of the national research funding agency, but they do not disseminateinformation about research through the Structural Funds; and ministries of science andeducation did not show how the Structural Funds contribute to their budgets. This maybe because ministries of finance have to report co-funding for the Structural Funds tothe European Commission: in general, member states ‘badge’ the funding as national, soit is impossible to determine how much the Structural Funds themselves have assisted.Our study found that research call programmes were being managed in some countriesby the Structural Funds agency of the Ministry of Finance, rather than by the nationalresearch agency, creating a ‘parallel’ system.
While public health research is not prioritised independently within the StructuralFunds for research infrastructures, human capacities or research programmes, in
9Cyprus, Latvia and Lithuania public health appeared to be supported within broaderhealth research. In other countries it is possible that some generic support comesthrough increased ministry of education funding to universities: but this contrasts withthe direct mention in many of the Operation Programmes of funding for engineeringand technical sciences, and indeed biotechnology for health sciences. Public healthresearch could compete if calls are developed appropriately, and decision-makingboards have the appropriate representation for decision-making. Lithuania appears tohave taken this forward with a programme for public health research, although thefields now covered could be widened further.
An underlying problem of priorities is the European Union’s priority of support forbusiness [11]. Research and innovation are beneficial for economic ‘growth’; yetmanufacturing is only a small part of the total of western European economies, andmore than 60% is now ‘services’. Innovation through human resources andtechnologies can be social as well as physical, and outside the factory skills, quality andachievements are determined as much by social as by technological factors. This isparticularly the case for public health, where national policy, professional practice andscientific knowledge interact, and implementation requires internalisation withincultures beyond commercial markets. There is a need to re-emphasise the importanceof not-for-profit research in science [16, 17].
Public health research could benefit substantially from the Structural Funds. Newinstitutes, research units and courses could develop within the expanding highereducation sector. The research activities do not require expensive laboratories andtechnical equipment (apart from computing). And public health is a field with a positivegender balance. The challenge is for ministries of health – which would benefitimportantly from investment in public health research – to recognise the opportunity.For the Structural Funds in 2007-2013, ministries of health put forward cases forsupport for both health systems and buildings – and were generally successful, withspecific Operational Programmes in most countries [7]. But, despite the highimportance of health in research agendas – in European and most national programmes- few ministries of health have internal structures that take a direct interest in research,and have not influenced the priorities of the Structural Funds (through their national
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ministries of finance). This situation is exacerbated by the historic links of the lifesciences with ministries of science rather than ministries of health, and the traditionalpreference of science academies for basic and ‘physical’ sciences rather than appliedand ‘social’ sciences.
The content of the EU programmes for 2014-2020 will be decided in 2012 and 2013through decisions between the Council of Ministers (member states), Parliament(political processes) and European Commission (assessments and implementation). TheStructural Funds remain a major part of the EU budget, after the Common AgriculturalPolicy. In the present funding period, the Structural Funds spend as much in support ofresearch as the EU’s official budget for research, yet without any of the controls, dataand policies that are needed to improve value. Moreover, the European Commission’sDirectorate for Regions which allocates and monitors the Structural Funds does not givepriority attention to research, and neither the Commission’s Directorate for Researchnor the Directorate for Health have information on how member states are usingStructural Funds for research.
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Table I. Research and the Structural Funds in the 12 EU new member states
Comment Research and the Structural Funds
BulgariaVery limited activityfor health research
Bulgaria has a low level of research funding, 0.50% of GDP (2008).The seven Operational Programmes do not directly identify R&D. Thefourth, Competitiveness, Axis 1.2 (€75m) includes ‘pro-innovativeinfrastructure’, ‘pro-innovative services and ‘innovation networks’ –with beneficiaries “R&D institutions and organizations, municipalities,private or public bodies including NGOs”.Also in April 2009, Operational Programme “Regional Development”allocated €17 million for support/upgrading of universities.
CYPRUSActively using SF forresearchprogrammes,including (small)public healthresearch
Cyprus has low expenditure on R&D at 0.49% (2009). Cyprus has threeprivate universities and no medical school (although one is developingin North Cyprus). Of €83 million R&D funds, 45% (€38m) was directlyfrom government funds, €19m from the universities’ budgets, €10mfrom abroad (including €8m from EU) and €16m from the privatesector (€5m pharmaceuticals).Cyprus has €640million Structural Funds. RTDI has been implementedthrough the Cyprus Research Promotion Foundation. There have beentwo National Research Frameworks (DESMI) - in 2008 €48 million, andfor 2009-2011 €40. These were allocated: €33.4m for natural sciences,
€16.6m social sciences, €14.6m engineering and technology, €10.2magricultural sciences, €5.1m humanities, €3.2m health and biologicalsciences (including public health research). Other State support forbiomedical research includes €5 million annually for Cyprus Instituteof Neurology and Genetics (University of Nicosia).
Czech RepublicStrong R&Dprogramme,includingbiomedicine but not
Czech Republic has medium level investment in R&D at 1.6% of GDP,with public sector investment 38% and private sector 62%.The Operational Programme Research for Development and Innovationhas €2 billion, which includes €685 million (33%) for equipment andinfrastructure, €685 million (33%) for R & D institutes focused on
14
public healthresearch applied research, strengthening their cooperation with industry(including hospitals) according to the needs of the region, €414 million(20%) for universities’ infrastructure of laboratories and IT, and €72million (3%) monitoring of projects and programmes, studies andanalysis, programme publicity, and training and consultancy services.A further operational programme for universities and Academies,funded through the Ministry of Education, Youth and Sports, provides
€154 million institutional support.The programme Call 1.2 (2009) for Regional R&D centres had 18successful applications, predominantly in technical engineering. InNov/Dec 2010, biomedicine has been favoured with a €100 millionmolecular genetics centre at Vestec near Prague for Charles University(the project coordinator is the former President of the Academy ofScience) and a €12 million Regional Centre of Applied MolecularOncology at Brno.
EstoniaStrong SF investmentin R&Dinfrastructures andresearchprogrammes. Nopublic healthresearch.
R&D in Estonia has grown from 0.6% of GDP in 2000 to 1.4% in 2009.Spend is 39% natural sciences, 19% engineering, humanities, 15%medical and health sciences, 12% humanities, 9% social sciences, 5%agricultural sciences. Over 2007-2013, Estonia receives 3.4 billion -European Regional Development Fund support of €1.86 billion,Cohesion Fund €1.15 billion euros, and European Social Fund €390million.ERDF supports €306 million for infrastructure and development ofinstitutions, small-scale research equipment, R&D in biotechnology andother targeted programmes, and international collaboration.Operational Programme for Human Resource Development, operatedby the Estonian Ministry of Education and Research receives €102million euros (plus €14m state co-funding). Programmes includeMobilitas, supporting postdoctoral research (€20 million euros),implemented by the Estonian Science Foundation (July 2011 there hadbeen five rounds of calls for ‘top researcher grants’), and state’sArchimedes Foundation funding internationalization of doctoralstudies (€32 million).
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HungaryStrong use of SF forR&D. Support toindustry and highereducation institutes.No focus for publichealth research.
There is a low rate of research investment in Hungary at 1% of GNP.The Structural Funds (€22.4 billion) are allocated through 15Operational Programmes of the National Development Plan. RTDIactivities are mainly supported under the Economic DevelopmentOperational Programme (EDOP). Priority 1 “R&D and innovation forcompetitiveness” has €822m over 7 years from ERDF for three fields:the promotion of market-oriented R&D; innovation clusters andtechnology parks; and R&D activities by enterprises.The Social Infrastructures Operational Programme supports researchand educational infrastructure at HEIs, and the Social RenewalOperational Programme for collaborative RTDI, including basicresearch. Together with EDOP, these have more funds than the mainnational Research and Technological Innovation Fund.
LatviaSF used actively forinfrastructures andR&D calls. Smallpublic healthresearch support.
Latvia has a low rate of research, 0.61% of GDP (2008).In the ESF operational programme Priority "Higher Education andScience" includes "Attraction of Human Resources to Science" (€47m)and "Support to Doctor’s and Master’s study programmes" (€58m). Butmany of the scheduled activities were cancelled with the financial crisis.In the ERDF 2.1 Priority “Science and Innovation” has €451m ERDFsupport. This includes “Science, Research and Development” forinvestigator-initiated proposals (€50m). In a call in 2010, from 177proposals 114 were financed. A second activity "Development of thescientific and research infrastructure" covers infrastructuraldevelopment in 10 National research centres and the development ofscientific computing network with total ERDF support €175m. Amongthese 10 centres is the national research centre in public health andclinical medicine.In the 3rd operational programme "Infrastructure and Services"(ERDF/CF), €168m is given to development of infrastructure for highereducation, including large equipment. Activity "Development of Scienceand Technology park of Riga", originally intended to support biomedicalresearch, has been put on hold because of absence of suitable land fordevelopment, as a consequence of privatisations.
Lithuania Lithuania has a relatively low level of research at 0.82% of GDP in 2007.
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Strong use of SF forresearch – industry,human capacitiesand programmes.Strong list of publichealth researchsupport.
The annual Structural Funds for Lithuania 2007-2013 are €1 bn, around15% of the total national budget. Planning with stakeholders wasdeveloped from 2005. Support for research and innovation is well-developed under all three priority areas.Operational Programme 1-3: ‘Enhancement of researchers’ capacities’,coordinated by the Ministry of Education and Science, includesdevelopment of scientists and researchers, thematic networks and R&Dtraining (€140m).Operational programme 2.1: ‘R&D for competitiveness and growth’ has
€602m, includes infrastructure projects, ‘high level research centres’,business parks and integrated studiesOperational Programme 3.2: Priority 1.4 Strengthening ofAdministrative Capacity and Increase of Efficient Public Administration(€178m) includes Priority 1-4.3 (€37m), which integrated science,study and business centres (valleys), joint research programmes,strengthening the Lithuanian Scientific Council, and the development ofmonitoring of science and studies.Research supported by this last measure include the analysis of publichealth care carried out by municipalities, studies to identify the scopeof public health services, the development of a monitoring system,creation of models for providing public health services, training andprofessional development of public health care specialists, creation of ademand planning system as well as improvement and development ofpublic health impact assessment.
Malta
Moderate use of SFfor public sectorresearchinfrastructures andhuman resources,but not public healthresearch.
In 2007, Malta spent 0.6% of GDP on research and development.Business contributed the largest proportion of funds with €21m (65%)(largely multinational firms undertaking in-house R&D), followed byhigher education €10m (31%), with public research organisations just
€1m (3.3%).Malta’s Structural and Cohesion Funds for 2007-2013 total €855m. Justunder 10% is allocated to ‘Knowledge & Innovation’, mainly forinfrastructures (eg the IT faculty at the university, strengtheninguniversity laboratories in engineering, biotechnology and chemistry,
€49m). Malta Enterprises, an agency working under the Ministry of
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Finance, receives €20m for a Life Sciences Centre (molecular genetics).An Educational Pathways Scholarship Scheme for Post-Graduatestudies (MSc, PhD) is established with €10m, and Centre for PolicyResearch and Training for the Public Sector €3.4m.
PolandVery large overall SFavailable, smallerproportion for R&D,focus ontechnologies, nopublic healthresearch
The research expenditure in Poland is low (0.61% GDP in 2008),mainly non-competitive public funding through a large number ofhigher education institutes and academies.The Structural Funds for Poland 2007-2013 at €67.3 billion are thelargest for any member state, allocated in four main programmes. Thesmallest, the Operational Programme Innovative Economy, with €8.85billion from ERDF, has two research-related programmes: ‘Researchand development of new technologies’ (€1.1 billion) coveringinformatics, technologies and biotechnologies (includes ‘new medicalproducts and techniques’).The Operational Programme Infrastructure and Environment (€27.9billion) includes Priority 12 ‘Health security and improving theefficiency of the health system’ (€350m from ERDF), although this isnot related to research. Priority 13, ‘Infrastructure of higher education’(€500m from ERDF) covers infrastructures, access and improving thequality of education through IT.In the Human Capital Programme (€9.7 billion) is Priority 4.2,‘Developing R&D staff qualifications and increasing awareness ofscience importance to economic growth’ (€61m.).Regional Operational Programmes (€16.6 billion) have been createdfor each of the 16 provinces. Some Regional Innovation Strategiesinclude innovation networks and R&D.
RomaniaSubstantial SFfunding, moderateuse for researchinfrastructures andhuman resources,and competitiveprogramme calls
Romania has a low level of R&D investment (0.58% GDP in 2008).There is growing use of competition in public funding of research, andof the structural funds to support research, but substantial publicbudget cuts in 2009.Romania gains €19.6 billion from EU Structural and Cohesion Funds.Funded by ERDF, the Operational Programme “Increase of economiccompetitiveness” includes Axis 2: Research, TechnologicalDevelopment and Innovation for competitiveness (€536m), which is
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include ‘health’ butnot public health. managed through the National Authority for Scientific Research andaddresses five of the nine priorities of the national RDI strategy,including (first) ‘Health’.The Operational Programme ‘Human Resources Development’ fundedby ESF, has Axis 1 with €797m for higher education, and includesUniversity education for the knowledge society’ and ‘Doctoral andpostdoctoral programmes in support of research’.
SlovakiaStrong SF use forresearch universityinfrastructures,human resourcesand programmecalls, includingclinical research.
Slovakia’s proportion of R&D was low at 0.49% by 2007. However, R&Dis the main thrust for the 2007-2013 Structural Funds, with €1.2 billionallocated for the Research and Development, €883m for Convergence,and €326m for Regional Competitiveness and Employment.Over €500m was put out to 13 calls in 2009, which included grants forresearch of around €1m each (including clinical research studies), for‘centres of excellence’ of around €4m (including environment andhealth, stroke and perinatology), and grants for SMEs, including severalfor biomedical technology.The Operational Programme Education, with a total of €617m, includesMeasure 2.1, support for tertiary education (€28m in 2009 call), as wellas Measure 2 2 ‘Support for life-long learning in the Health sector’, withsub-objectives of building human resources for the health system andpromoting continuing education (no calls yet under this heading).The Operational Programme, Competitiveness and Economic Growthincludes a thematic programme for universities’ buildings andinfrastructures, with a budget of €1.2bn
SloveniaModerate SF use forR&D publicinfrastructures,SMEs andtechnology. Nopublic healthresearch.
Slovenia has a medium level of investment in R&D at 1.6% of GDP in2008.The total EU Structural Funds are €4.2 billion, divided into fiveprogrammes. The first of these, Strengthening Regional DevelopmentPotential has €1.7 billion (40%), with five operational programmes, ofwhich the first ‘Competitiveness and Research Excellence’ receives
€402m (24%).In a competitive call for 2009-2013, eight Centres of Excellence forinfrastructures programmes and operation were chosen (out of 60applications), each receiving €10m: all were in technology, with one in
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biochemistry. Seven Competence Centres received €7m each, with onein biotechnology and one in biomedical engineering.
